Skip to content
Screener

Aclaris Therapeutics ACRS Other Income (Expense)

Other Income (Expense) at other companies

Incyte logo
IncyteINCY
$6.28M-14.1%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$2.67M-39.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$4.82M-237%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$1M+74.7%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$98K+45.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$18.21M-55.0%

Segments

By segment

See full
Single Reportable$2.73M-8.3%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.56M+389%
Enterprise value$851.24M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092065
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other income:
Interest income1,7612,0183,2754,184
Non-cash royalty income9729611,8261,794
Total other income2,7332,9795,1015,978
Net loss$(21,505)$(15,429)$(41,329)$(30,514)
Net loss per share, basic and diluted$(0.15)$(0.13)$(0.30)$(0.25)
Weighted average common shares outstanding, basic and diluted142,736,848122,580,967135,811,921122,486,162
Other comprehensive (loss) income:

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's other income (expense)?
Aclaris Therapeutics (ACRS) reported other income (expense) of $2.73M in Q2 2026.
How has Aclaris Therapeutics's other income (expense) changed year-over-year?
Aclaris Therapeutics's other income (expense) decreased by 8.3% year-over-year, from $2.98M to $2.73M.
What is the long-term trend for Aclaris Therapeutics's other income (expense)?
Over 4 years (2021 to 2025), Aclaris Therapeutics's other income (expense) has grown at a 74.6% compound annual growth rate (CAGR), from -$1.23M to $11.45M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Aclaris Therapeutics's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude